Evaluating the Diagnostic Utility of High-Frame-Rate Contrast-Enhanced Ultrasound and a Nomogram for Lymphoma Assessment - Top-Institutions - MDSpire

Evaluating the Diagnostic Utility of High-Frame-Rate Contrast-Enhanced Ultrasound and a Nomogram for Lymphoma Assessment

  • By

  • Yu Song

  • Yahan Zhang

  • Linlin Zhang

  • Ying Che

  • Manxi Li

  • November 19, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Diagnostic Radiology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Radiology

  • #3

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Diagnostic Radiology
    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Radiology
    • Oncology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hematology
    • Diagnostic Radiology
    • Oncology

Original Source(s)

Evaluating the Diagnostic Utility of High-Frame-Rate Contrast-Enhanced Ultrasound and a Nomogram for Lymphoma Assessment

  • by Yu Song, Yahan Zhang, Linlin Zhang, Ying Che, Manxi Li

  • November 19, 2025

Related Content

Case Report: Extranodal marginal zone B-cell lymphoma in the lateral ventricle: literature review

Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.